The Role of Frequent Point-of-care Molecular Workplace Surveillance for Miners: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for The Role of Frequent Point-of-care Molecular Workplace Surveillance for Miners (NCT04977050), a non-randomized na study. The primary outcome is Number of Participants Screened (Molecular).

2. Clinical Question

The study’s stated objective was to assess frequent point-of-care testing as a workplace surveillance tool for monitoring and preventing SARS-CoV-2 spread in miners. Its brief summary also states an interest in discovering host risk factors. Those aims describe the rationale, but the posted primary endpoint is a screening count. The registry record does not report results for infection, transmission, or host risk factors. Consequently, the central question that can be assessed from the posted endpoint is whether screening activity was counted and reported, not whether surveillance reduced infection. The record’s differing descriptions of molecular and antigen testing also make the exact screening procedure unclear.

3. Trial Design

The registry describes a parallel, non-randomized study with no masking. It lists an enrollment of 230 and a status of completed. The study start date is 2021-02-22, and the primary completion date is 2022-10-31. The listed phase is NA. The sponsor is the University of New Mexico.

The two arms are defined by mine site rather than by random assignment. The intervention site is a New Mexico mine; the control site is a Wyoming mine. The brief summary describes the Wyoming mine as similar and says both mines are operated by the same company. The registry does not report individual assignment procedures or detailed site-matching criteria. Because each arm is tied to a different site, the comparison is also a comparison between those locations. Differences between sites could therefore be entangled with differences in screening, even if the mines share an operator.

The intervention-site arm description lists nasal swabs for antigen testing every other work shift and serological testing at 3 months. The control-site description lists serological testing at 3 months. However, the brief summary describes alternate-day molecular screening at the intervention site, while the named intervention is an antigen test. This inconsistency leaves the exact screening method uncertain in the registry record.

The registry record does not report the rationale for the enrollment target, a sample-size justification, or a statistical analysis plan. It also does not report the detailed procedures for enrollment, follow-up, or handling differences between the sites. The completed status indicates the study is recorded as completed; it does not, on its own, establish that all planned measurements or analyses are reported.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants Screened (Molecular), measured over 12 months.

The primary endpoint is titled “Number of Participants Screened (Molecular).” Its unit is participants, its registered type is a count of participants, and its timeframe is 12 months. The description calls it a rapid antigen test for COVID-19. These labels do not align fully: the title refers to molecular screening, while the description and named intervention refer to antigen testing. The registry record does not resolve the discrepancy.

A screening count is a process measure. In general, it can describe whether and how extensively a surveillance procedure was carried out. It does not itself establish how many participants had infection, whether transmission changed, or whether screening prevented infection. Those are distinct clinical or epidemiologic outcomes and are not the posted primary endpoint.

The endpoint could be useful for understanding implementation because a workplace surveillance approach depends on screening being carried out. But a count alone does not describe the timing or completeness of screening for each participant, nor does it show whether test results led to any particular action. The registry record does not report a result for this primary endpoint, its distribution across the arms, or a statistical comparison. It also does not clarify whether “molecular” in the endpoint title or “antigen” in the description reflects the test actually used.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The statistical information in the registry is limited. It records a non-randomized, parallel design, a binary outcome classification, one primary outcome measure, and no analyses. The primary measure is described as a count of participants screened, which does not align neatly with the binary classification. The registry record does not report a detailed statistical methods plan, an estimator, a model, covariates, or an approach for comparing the sites.

What does non-randomized allocation imply?

In general, random assignment helps make comparison groups similar with respect to measured and unmeasured characteristics, on average. With non-randomized assignment, that protection is absent. Here, the arms correspond to a New Mexico mine and a Wyoming mine, so site and surveillance condition are linked. Differences in workforce characteristics, local circumstances, or site procedures could be associated with the observed outcomes. A statistical adjustment can sometimes address measured differences, but it cannot automatically remove unmeasured differences. The registry record does not report whether any adjustment was planned or performed.

The parallel label indicates that the two arms represent separate groups under different site conditions, rather than a reported crossover design. The registry describes no masking. In general, lack of masking can affect how procedures are carried out or how outcomes are recorded, depending on the outcome and study processes. For a count of screening activity, accurate interpretation would depend on clear definitions and consistent recording. Those operational details are not reported in the registry record.

What can a screening count tell readers?

A count of participants screened describes an amount of activity only when the counting rule and eligible population are clear. In general, counts may be interpreted differently depending on whether they represent people ever screened, screening occasions, or people meeting a specified testing schedule. The registered unit says participants, but the record does not provide further counting rules or an observed count. The timeframe is 12 months. The endpoint title calls the test molecular, whereas its description calls it antigen testing. These unresolved details prevent a precise interpretation of what the count would represent.

The registry classifies the outcome as binary, but names the primary parameter as a count of participants. A binary outcome ordinarily represents whether an event or condition is present for each participant. A count may instead refer to the number of people meeting a screening definition or to repeated testing activity, depending on the definition. Since the record does not explain the classification or give a result, no specific statistical model can be inferred from these labels.

How should uncertainty be understood?

In general, a point estimate gives a summary of an observed quantity, while a confidence interval conveys the uncertainty around that estimate under the analysis assumptions. A p-value is a measure of how compatible the observed data are with a specified null model; it is not a measure of clinical importance or the probability that a hypothesis is true. Neither an estimate nor an interval nor a p-value for the primary endpoint is reported in the registry record. There is no basis for describing the precision or statistical significance of a site comparison.

The registry records planning assumptions for illustrative sample-size calculations: a two-sided significance level of 0.05, equal allocation between arms, and a normal approximation. It says the effect to detect is a stated fraction of the observed effect, and distinguishes calculations for time-to-event outcomes from calculations for other outcomes. These are planning illustrations, not observed power. The registry record does not report the numerical illustrations in the material analyzed here, an observed primary effect, or a sample-size justification from the study’s own design. The assumptions should not be read as proof that the study was designed to detect a particular effect.

Why does over-dispersion matter in general?

For count outcomes, a model that assumes a particular amount of variability may give misleading uncertainty estimates if the observed counts vary more than that model allows. This is called over-dispersion. In general, analysts may use a model or variance estimate suited to the outcome’s distribution and structure. Whether over-dispersion is relevant depends on how screening was counted and how the data varied. The registry record reports neither the count data nor the analysis model, so it is not possible to assess this issue for this study.

The absence of a reported analysis is distinct from a finding of no effect. It means that the registry record does not provide the statistical results needed to estimate or test the primary comparison. Any broader analysis would require outcome data and a clear account of the endpoint definition, site structure, and analysis choices.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Intervention Site", "Controled Site")
n      <- c(169, 61)
events <- c(169, 61)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Intervention Site  169  169  100.0  97.8  100.0  97.8  100.0  97.9  100.0
ARM  Controled Site  61  61  100.0  94.1  100.0  94.1  100.0  94.2  100.0

11. Multiplicity, Missing Data and Analysis Populations

The registry lists one primary outcome measure and no analyses. It does not report a statistical analysis plan or identify a family of confirmatory hypotheses. Multiplicity refers, in general, to the increased chance of false-positive findings when many hypotheses or outcomes are tested. Without a reported set of analyses, it is not possible to determine whether multiplicity adjustments were planned or needed. The absence of reported analyses should not be interpreted as evidence that multiplicity was addressed.

Missing-data procedures are not reported in the registry record. The record does not describe whether screening data, serological data, or follow-up information were incomplete, how completeness was assessed, or how missing observations would be handled. In general, missingness can affect an estimate when the chance that data are absent is related to participant characteristics or outcomes. The direction and size of such effects depend on the data and the reasons for missingness; they cannot be determined from the registry entries.

Analysis populations are also not reported. The record does not specify whether analyses would include all enrolled miners, only participants with available testing information, or another defined group. The enrollment figure does not by itself establish which participants contributed to a particular endpoint or analysis. No participant flow or endpoint-specific denominator is reported for the primary screening measure.

The registry lists adverse-event risk denominators for each group, but those entries do not define the analysis population for the primary endpoint. They should not be substituted for a screening denominator. Without a reported endpoint result, analysis population, and missing-data account, readers cannot evaluate the completeness or representativeness of the primary outcome data.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The adverse-event fields list no serious events, no other events, and no deaths for either group. The intervention-site group has 169 participants listed at risk, and the control-site group has 61 listed at risk. The registry lists no serious adverse-event terms.

These are registry entries, not a detailed safety analysis. A zero count means that no events are recorded in the relevant field; it does not by itself establish that the event was actively sought, that all follow-up was complete, or that no event occurred outside the record’s reporting procedures. The registry record does not describe event definitions, collection methods, monitoring, or the period used for safety follow-up. It also does not provide a safety comparison or uncertainty estimate.

The groups are non-randomized and correspond to different mine sites, so the entries should not be interpreted as a controlled estimate of comparative risk. The risk denominators shown for adverse events are specific to those fields and should not be treated as the primary endpoint denominator. The posted safety figures describe what the registry records, but do not establish a broader safety conclusion about the screening approach.

13. What the Result Does, and Does Not, Mean

The record establishes that the study was registered as a completed, non-randomized, parallel comparison involving miners at intervention and control mine sites. It describes frequent workplace screening as the intervention concept and identifies the number of participants screened over 12 months as the primary endpoint. It also records the test name and arm descriptions, although those descriptions disagree about whether the screening was molecular or antigen-based.

The record does not report the primary endpoint result, an analysis comparing the sites, or results for SARS-CoV-2 infection or transmission. It therefore cannot show from the posted results whether screening activity differed between the sites, whether infection was reduced, or whether the stated aims were achieved. No reported estimate or interval is available to describe the magnitude or precision of a primary comparison.

In general, a workplace screening count can indicate implementation activity, but it is not equivalent to an infection outcome. Even a clearly reported count would not by itself show that testing changed infection risk. Such a conclusion would require relevant outcome data and an analysis that accounts for the study design. Here, the non-randomized site-based comparison adds the possibility that differences between mines are mixed with differences in surveillance.

The safety entries record zero events in the listed categories, but they do not supply a complete account of safety ascertainment. Likewise, planning assumptions for illustrative sample-size calculations do not replace results or establish observed power. The appropriate reading is therefore descriptive: the registry documents the study’s aims, design, endpoint label, and selected safety entries, while leaving the principal efficacy-style results and analysis methods unreported.

14. Why This Trial Matters Statistically

This study raises a useful statistical question about how workplace surveillance should be evaluated: screening activity and infection outcomes are related but distinct. A count of participants screened can describe implementation, while evidence about infection or transmission requires those outcomes to be measured and reported separately. Keeping the endpoint definition aligned with the study’s stated objective is essential for interpreting what a result could establish.

The site-based, non-randomized design also illustrates a common challenge in field research. When an intervention is implemented at one worksite and a comparison condition at another, differences between sites may complicate causal interpretation. In general, thoughtful design, transparent measurement, and appropriate analysis are needed to distinguish an intervention association from other site differences. The registry record does not report an analysis strategy for doing so.

Clear endpoint naming matters as well. Here, “Molecular” in the primary endpoint title conflicts with the antigen-test description and the named intervention, while the brief summary describes molecular surveillance. That ambiguity affects reproducibility and the meaning of any screening count. A clear record should specify what test was used and what counted as a screened participant.

Finally, a completed status is not a substitute for posted outcome results. Statistical interpretation depends on accessible endpoint data, estimates, uncertainty, and methods. The absence of those elements in the registry record limits what can be concluded, while highlighting why complete and internally consistent reporting matters in applied clinical and occupational research.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most direct limitation of the available record is that it does not report the primary endpoint result or any analysis. Without those results, the amount of screening activity and any difference between the sites cannot be assessed. The record also does not report infection outcomes, despite describing prevention of SARS-CoV-2 spread as an objective.

The intervention is described inconsistently. The primary endpoint title and brief summary refer to molecular screening, while the named intervention and endpoint description specify an antigen test. The intervention-site arm description says antigen testing every other work shift; the brief summary describes molecular tests on alternate workdays. The registry record does not reconcile the test type or the schedule.

The non-randomized design assigns conditions by mine site, with the intervention site in New Mexico and the control site in Wyoming. This makes site differences a potential source of confounding. The record does not report a statistical adjustment plan, detailed site-comparability information, or participant-level characteristics sufficient to assess the extent of this concern.

Other methodological details are not reported in the registry record, including eligibility criteria, endpoint counting rules, missing-data procedures, analysis populations, and a full statistical analysis plan. The adverse-event entries likewise lack detail on event definitions and ascertainment. These omissions do not prove that procedures were absent, but they limit what can be evaluated from the registry record. The reported sample-size assumptions are planning illustrations and do not provide a substitute for trial-specific design justification or outcome analysis.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: The Role of Frequent Point-of-care Molecular Workplace Surveillance for Miners — NCT04977050.
• Registry record last updated 2024-04-03; status last verified 2024-04.
• Results first posted 2024-04-03.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes a completed, non-randomized, parallel study sponsored by the University of New Mexico, with an enrollment of 230 and no masking. The study compares an intervention mine site in New Mexico with a control mine site in Wyoming. Its stated objective concerns frequent workplace surveillance for SARS-CoV-2, while the primary endpoint is the number of participants screened over 12 months.

The record is inconsistent about whether the screening test was molecular or antigen-based. It reports no primary endpoint result and lists no analyses. Adverse-event fields record zero serious events, zero other events, and zero deaths in both groups; the record provides no detailed safety methods. The registry record therefore documents the intended comparison and selected design details, but does not provide results sufficient to assess screening activity or infection outcomes.